Terms: = Mucinous carcinoma AND ESR1, ESR, 2099, ENSG00000091831, RP1-130E4_1, NR3A1, ESRA, DKFZp686N23123, ER, Era AND Clinical Outcome
87 results:
1. Impact of histological subtypes on clinical outcome of endocervical adenocarcinoma.
Tian X; Liu P; Kang S; Cui Z; Sun L; Lang J; Chen C
Eur J Surg Oncol; 2024 Apr; 50(4):107977. PubMed ID: 38373385
[TBL] [Abstract] [Full Text] [Related]
2. Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer.
Reichenbach J; Fraungruber P; Mayr D; Buschmann C; Kraus FBT; Topalov NE; Chelariu-Raicu A; Kolben T; Burges A; Mahner S; Kessler M; Jeschke U; Czogalla B; Trillsch F
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8719-8728. PubMed ID: 37131060
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological and molecular characterization of biphasic hyalinizing psammomatous renal cell carcinoma: further support for the newly proposed entity.
Wang XT; Xia QY; Fang R; Zhang RS; Ye SB; Li R; Wang X; Lu ZF; Ma HH; Zhou XJ; He HY; Zhao M; Rao Q
Hum Pathol; 2022 May; 123():102-112. PubMed ID: 35192800
[TBL] [Abstract] [Full Text] [Related]
4. [A tumor of the uterus with a falsely benign aspect].
Tauziède-Espariat A; Georges O
Ann Pathol; 2022 Nov; 42(6):462-466. PubMed ID: 35034828
[TBL] [Abstract] [Full Text] [Related]
5. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract] [Full Text] [Related]
6. The Decline of Salivary Adenocarcinoma Not Otherwise Specified as a Tumor Entity: Reclassification Using Contemporary Immunohistochemical Profiling and Diagnostic Criteria.
Rooper LM; Mansour M; Yonescu R; Oliai BR; Bishop JA; Westra WH
Am J Surg Pathol; 2021 Jun; 45(6):753-764. PubMed ID: 33284193
[TBL] [Abstract] [Full Text] [Related]
7. mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases.
Chang WC; Zhang YZ; Wolf JL; Hermelijn SM; Schnater JM; von der Thüsen JH; Rice A; Lantuejoul S; Mastroianni B; Farver C; Black F; Popat S; Nicholson AG
Histopathology; 2021 Feb; 78(3):434-444. PubMed ID: 32810914
[TBL] [Abstract] [Full Text] [Related]
8. Predictive factors of complete pathological response in patients with locally advanced rectal cancer.
Engel RM; Oliva K; Koulis C; Yap R; McMurrick PJ
Int J Colorectal Dis; 2020 Sep; 35(9):1759-1767. PubMed ID: 32474708
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic Impact of Histopathologic Features in Pulmonary Invasive mucinous Adenocarcinomas.
Chang WC; Zhang YZ; Lim E; Nicholson AG
Am J Clin Pathol; 2020 Jun; 154(1):88-102. PubMed ID: 32215558
[TBL] [Abstract] [Full Text] [Related]
10. Predictive Impact of mucinous Tumors on the clinical outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Rosati G; Galli F; Cantore M; Bergamo F; Banzi M; Zampino MG; Mattioli R; Cardellino GG; Ronzoni M; Di Bartolomeo M; Tamberi S; Marchetti P; Rimassa L; Corsi D; Bochicchio AM; Artioli F; Labianca R; Galli F; Rulli E; Bilancia D; Bregni G;
Oncologist; 2020 Jun; 25(6):e928-e935. PubMed ID: 31943506
[TBL] [Abstract] [Full Text] [Related]
11. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract] [Full Text] [Related]
12. Ultrasound features and clinical outcome of patients with malignant ovarian masses diagnosed during pregnancy: experience of a gynecological oncology ultrasound center.
Moro F; Mascilini F; Pasciuto T; Leombroni M; Li Destri M; De Blasis I; Garofalo S; Scambia G; Testa AC
Int J Gynecol Cancer; 2019 Sep; 29(7):1182-1194. PubMed ID: 31326950
[TBL] [Abstract] [Full Text] [Related]
13. clinical outcome of Patients With Malignant Tumors Associated With Mature Cystic Teratomas of the Ovary: A Retrospective Multicenter Italian Study.
Gadducci A; Giuliani D; Cosio S; Lissoni A; Ferrero AM; Landoni F
Anticancer Res; 2019 May; 39(5):2513-2517. PubMed ID: 31092447
[TBL] [Abstract] [Full Text] [Related]
14. Signet ring cell component predicts aggressive behaviour in colorectal mucinous adenocarcinoma.
Song IH; Hong SM; Yu E; Yoon YS; Park IJ; Lim SB; Kim JC; Yu CS; Kim J
Pathology; 2019 Jun; 51(4):384-391. PubMed ID: 31029443
[TBL] [Abstract] [Full Text] [Related]
15. Post-operative wall shear stress in the superior mesenteric artery: Biomarker of long term outcome in patients with residual disease after incomplete cytoreductive surgery for pseudomyxoma peritonei.
Barral M; El Sanharawi I; Eveno C; Dohan A; Launay JM; Lo Dico R; Pocard M; Bonnin P
Eur J Surg Oncol; 2019 Sep; 45(9):1727-1733. PubMed ID: 30871885
[TBL] [Abstract] [Full Text] [Related]
16. Micropapillary Cervical Adenocarcinoma: A Clinicopathologic Study of 44 Cases.
Alvarado-Cabrero I; McCluggage WG; Estevez-Castro R; Pérez-Montiel D; Stolnicu S; Ganesan R; Vella J; Castro R; Canedo-Matute J; Gomez-Cifuentes J; Rivas-Lemus VM; Park KJ; Soslow RA; Oliva E; Valencia-Cedillo R
Am J Surg Pathol; 2019 Jun; 43(6):802-809. PubMed ID: 30864975
[TBL] [Abstract] [Full Text] [Related]
17. Calpain system protein expression and activity in ovarian cancer.
Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
[TBL] [Abstract] [Full Text] [Related]
18. Patient Survival after Surgical Management in Intrathoracic Pseudomyxoma peritonei.
Kawaguchi Y; Hanaoka J; Ohshio Y; Okamoto K; Kaku R; Hayashi K; Shiratori T; Yoden M
Ann Surg Oncol; 2019 Jan; 26(1):238-243. PubMed ID: 30421066
[TBL] [Abstract] [Full Text] [Related]
19. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract] [Full Text] [Related]
20. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
[TBL] [Abstract] [Full Text] [Related]
[Next]
